Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation, alleging that the company made misleading statements regarding its financial health and the impact of customer spending on its business [3][4]. Financial Performance - For Q4 2024, 3D Systems reported a non-GAAP loss of $0.19 per share, missing consensus estimates by $0.08 [6]. - Q4 revenue was $111 million, representing a 3.4% year-over-year decline and falling short of expectations by $4.17 million [6]. - Full-year revenue for 2024 was $440.1 million, a 10% decline year-over-year attributed to lower hardware sales and macroeconomic challenges [6]. - The company experienced a $9 million revenue reduction in Q4 related to revised accounting estimates for its Regenerative Medicine Program [6]. Recent Developments - On March 26, 2025, 3D Systems disclosed its Q4 and full-year 2024 financial results, leading to a nearly 21% decline in its stock price [4]. - On May 12, 2025, the company announced its Q1 2025 results, revealing a revenue of $94.5 million, an 8% year-over-year decline, and a net loss of $37 million, more than double the loss from Q1 2024 [6]. - The company withdrew its full-year 2025 guidance, citing ongoing softness in customer capital spending and broader macroeconomic uncertainty [4][6]. Legal Context - The class action lawsuit represents investors who purchased securities between August 13, 2024, and May 12, 2025, with a deadline of August 12, 2025, to file a lead plaintiff motion [1]. - Allegations include that 3D Systems understated the impact of weakened customer spending and overstated its ability to navigate challenging market conditions [3].

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation, alleging that the company made misleading statements regarding its financial health and the impact of customer spending on its business [3][4]. Financial Performance - 3D Systems reported a Q4 non-GAAP loss of $0.19 per share, missing consensus estimates by $0.08 [6] - Q4 revenue was $111 million, representing a 3.4% year-over-year decline and falling short of expectations by $4.17 million [6] - Full-year revenue for 2024 was $440.1 million, a 10% decline year-over-year attributed to lower hardware sales and macroeconomic challenges [6] - The company experienced a $9 million revenue reduction in Q4 due to revised accounting estimates for its Regenerative Medicine Program [6] - In Q1 2025, revenue was $94.5 million, an 8% year-over-year decline, and below the consensus estimate of $99.5 million [6] - The net loss for Q1 2025 was $37 million (or $0.28 per share), more than double the $16 million loss in Q1 2024 [6] - An adjusted loss of $0.21 per share was reported, worse than the expected $0.14 loss [6] - The adjusted EBITDA was negative at $23.9 million, compared to a $20.1 million loss in Q1 2024 [6] Class Action Details - The class action lawsuit covers investors who purchased securities between August 13, 2024, and May 12, 2025 [1] - Investors have until August 12, 2025, to file a lead plaintiff motion [1] - The lawsuit claims that 3D Systems failed to disclose the negative impact of weakened customer spending and changes in its partnership with United Therapeutics Corporation [3]

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation and certain officers for alleged violations of federal securities laws during the Class Period from August 13, 2024, to May 12, 2025, seeking damages for misleading statements regarding the company's business and operations [1][6][7]. Company Overview - 3D Systems provides 3D printing and digital manufacturing solutions across various regions, earning revenue from two segments: Healthcare Solutions and Industrial Solutions [3]. - The Healthcare Solutions segment includes dental, medical devices, personalized health services, and a Regenerative Medicine Program focused on additive manufacturing for human organ transplantation [4]. Financial Performance - In Q4 2024, 3D Systems reported non-GAAP earnings-per-share of -$0.19, missing estimates by $0.08, with sales revenue of $111 million, a 3.4% year-over-year decline [8]. - For the full year 2024, sales were $440.1 million, a 10% decrease from the previous year, attributed to lower hardware systems sales due to macroeconomic factors [8]. - In Q1 2025, revenue was $94.5 million, down 8% year-over-year, with a net loss of $37 million, more than doubling the loss from Q1 2024 [9]. Market Response - Following the Q4 2024 results, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [8]. - After the Q1 2025 results, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [10]. Legal Allegations - The lawsuit alleges that during the Class Period, the company and its officers made materially false and misleading statements, including underestimating the impact of weakened customer spending and overstating the resilience of the business [6][7]. - The updated milestone criteria in the United Partnership were claimed to negatively impact the company's Regenerative Medicine Program revenue [7].

Core Viewpoint - A class action lawsuit has been filed against 3D Systems Corporation and certain officers for alleged violations of federal securities laws during the Class Period from August 13, 2024, to May 12, 2025, seeking damages for misleading statements regarding the company's business and operations [1][8]. Company Overview - 3D Systems provides 3D printing and digital manufacturing solutions across various regions, earning revenue from two segments: Healthcare Solutions and Industrial Solutions [4]. - The Healthcare Solutions segment includes dental, medical devices, personalized health services, and a Regenerative Medicine Program focused on 3D printing organs for transplantation [4][5]. Financial Performance - In March 2025, 3D Systems projected revenue for 2025 to be between $420 million and $435 million, indicating flat to modest growth, with a non-GAAP Gross Profit Margin of 37% to 39% and non-GAAP Operating Expense of $200 million to $220 million [7]. - The company reported a Q4 2024 non-GAAP earnings-per-share of -$0.19, missing estimates, and a sales revenue of $111 million, down 3.4% year-over-year [9]. - For full-year 2024, sales were reported at $440.1 million, a 10% decrease from the previous year, attributed to lower hardware systems sales due to macroeconomic factors [9]. - In Q1 2025, revenue was $94.5 million, down 8% year-over-year, with a net loss of $37 million, more than doubling the loss from Q1 2024 [10]. Market Reaction - Following the announcement of disappointing financial results, 3D Systems' stock price fell significantly, dropping 20.96% to $2.15 per share on March 27, 2025, and further declining 26.6% to $1.87 per share on May 13, 2025 [9][11]. Allegations in Lawsuit - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements about the company's business resilience and the impact of weakened customer spending, as well as failing to disclose the negative effects of updated milestone criteria on the Regenerative Medicine Program revenue [8].

Core Viewpoint - A class action has been filed against 3D Systems Corporation for allegedly misleading investors regarding its business prospects and financial performance [1][2]. Group 1: Allegations and Financial Performance - The complaint alleges that 3D Systems understated the impact of weakened customer spending and overstated its resilience in challenging industry conditions [2]. - The updated milestone criteria in the United Partnership are claimed to negatively impact the revenue of the Company's Regenerative Medicine Program [2]. - On March 26, 2025, 3D Systems announced disappointing financial results for Q4 and full-year 2024, leading to a stock price drop of $0.57 per share, or 20.96%, closing at $2.15 on March 27, 2025 [3]. - For Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, missing consensus estimates of $99.5 million, and a net loss of $37 million, or $0.28 per share, more than doubling the $16 million loss from Q1 2024 [4]. - The adjusted loss per share was $0.21, deeper than the consensus estimate of a loss of $0.14, and adjusted EBITDA showed a loss of $23.9 million, worsening from a $20.1 million loss in Q1 2024 [4]. - The Company attributed its disappointing results to a decline in material sales, particularly due to inventory management issues in the dental segment of its Healthcare Solutions [4]. - 3D Systems withdrew its full-year 2025 outlook, citing prolonged softness in customer capital spending and macroeconomic uncertainty [4]. - Following the Q1 results announcement, the stock price fell $0.68 per share, or 26.6%, closing at $1.87 on May 13, 2025 [4].

Core Viewpoint - A class action has been filed against 3D Systems Corporation for allegedly misleading investors about its business prospects, particularly regarding customer spending and revenue impacts from updated milestone criteria in its Regenerative Medicine Program [1][2]. Financial Performance - On March 26, 2025, 3D Systems announced disappointing financial results for Q4 and full-year 2024, leading to a stock price drop of $0.57 per share, or 20.96%, closing at $2.15 on March 27, 2025 [3]. - For Q1 2025, 3D Systems reported revenue of $94.5 million, down 8% year-over-year, missing consensus estimates of $99.5 million. The company also reported a net loss of $37 million, or $0.28 per share, more than doubling the $16 million loss from Q1 2024 [4]. - The adjusted loss per share was $0.21, worse than the consensus estimate of a loss of $0.14 per share, and adjusted EBITDA showed a loss of $23.9 million, worsening from a $20.1 million loss in Q1 2024 [4]. - The company withdrew its full-year 2025 outlook due to prolonged softness in customer capital spending and macroeconomic uncertainty, resulting in a further stock price decline of $0.68 per share, or 26.6%, closing at $1.87 on May 13, 2025 [4].